clinical trial · NCT06003751
A Study of PER-001 in Participants With Diabetic Retinopathy
Perfuse Therapeutics, Inc.·phase2·completed·n = 27
Diabetic RetinopathyPER-001 Intravitreal Implant - Low DosePER-001 Intravitreal Implant - High DosePER-001 Intravitreal Implant - Sham
brief summary
This is a Phase 2a, randomized, single-masked (participant), sham controlled clinical study.
started
Aug 5, 2023
primary completion
Apr 3, 2025
completion
Dec 10, 2025
last updated
Jun 5, 2026
detailed description
This clinical study is a randomized, single-masked (participant) study to further investigate the ocular and systemic safety and tolerability of the two dose levels of PER-001 Intravitreal Implants in participants with diabetic retinopathy. Participants who meet entry criteria will be randomized to receive either dose of PER-001 or sham control. A total of approximately 24 participants (12 in each Cohort, will be randomized).
official title
A Phase 2a Study to Evaluate Safety and Tolerability After Single Administration of PER-001 Intravitreal Implant in Participants With Diabetic Retinopathy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol